On April 12, 2023 — Yaocheng Health Science&Technology (hereinafter referred to as "Yaocheng" ) announced its partnership with Simcere Zaiming, an innovative oncology drug company under the Simcere Pharmaceutical Group, to successfully deploy the AuroraPrime Create system (hereinafter referred to as "Prime Create") for clinical trial document generation at the end of March. The system will be used for clinical trial protocol design and CSR (Clinical Study Report) writing, aiming to empower Simcere Zaiming's medical team to improve content writing and team collaboration efficiency, construct an enterprise-level clinical trial knowledge base, and realize the knowledge accumulation and digitization of trial documents.

Ms. Wenjie Song, Senior Vice President of Simcere Zaiming, said: "Innovation and development are our core competitiveness. We attach great importance to the entire process of each clinical trial project, from clinical trial design, to trial operation, to biostatistics and CSR writing. We always adhere to a rigorous attitude to ensure the scientific validity of every innovation and development result, which often requires huge manpower and time costs. Advanced computer technology or system products may empower enterprise clinical trials and improve operation efficiency while ensuring strict compliance. This cooperation with Yaocheng starts with the document writing scenario, hoping to optimize the overall workflow and improve writing and collaboration efficiency through an enterprise-level system. With the help of machine learning and other technologies, we aim to understand and extract current and past document content and trial data, allowing the smooth flow of document content and trial data in the system, and ultimately achieve the digitization of clinical trial documents."

Ms. Alice Hsu, Senior Vice President of Clinical Technology Services and Consulting at Yaocheng, said: "We are honored to provide ZAIMING with our innovative clinical trial system, Prime Create. Prime Create is not only an important document writing tool for medical teams, but also connects to our Clinical Logic Engine, which understands structured content. In the process of medical teams constantly producing plans and CSR documents and importing relevant content, Prime Create will accumulate valuable knowledge and experience of clinical trials for enterprises. This not only provides reliable content reference for subsequent trial document writing, but also makes intelligent-assisted generation of professional document content possible. Prime Create empowers medical writing teams to improve content quality and efficiency, laying a solid foundation for more document content-based digital scenarios required by enterprises."

About Simcere Zaiming:

Simcere Zaiming is a pharmaceutical company specializing in oncology, and a subsidiary of Simcere Pharmaceutical Group Limited, that focuses on the R&D, production and commercialization of innovative cancer therapeutics. The company was formed in 2023 and is committed to solving unmet clinical needs for cancer patients in China and around the world by developing breakthrough treatments. Simcere Zaiming has an innovative R&D pipeline with differentiated clinical value, among which 15 assets are currently in clinical trials. In addition to the company’s R&D portfolio, Simcere Zaiming is marketing three innovative drugs, COSELA®, Endostar®, and Envafolimab®. By collaborating with partners globally, Simcere Zaiming strives to bring potentially new innovative therapeutics to cancer patients worldwide.

About Yaocheng Health Science&Technology：

Yaocheng is focused on the clinical research and development field of life sciences, and is committed to creating a globally leading new generation of clinical research SaaS platform. It leverages cloud computing, big data, AI, and other technologies to empower the trial design, data management, and operation of life science research and development, ensuring clinical data consistency, improving design and execution efficiency, controlling cost input, accelerating the commercialization of innovative drugs and new medical devices, and benefiting human health.